BACKGROUND: Nonoperative options for @entity75 ( @entity75 ) of the talar dome are limited, and currently, there is a lack of scientific evidence to guide management. PURPOSE: To evaluate the short-term efficacy and safety of platelet-rich plasma ( @entity7676 ) compared with hyaluronic acid (HA) in reducing @entity158 and disability caused by @entity75 of the ankle. STUDY DESIGN: Randomized controlled trial; Level of evidence, 2. METHODS: Thirty-two @entity1 aged 18 to 60 years were allocated to a treatment by intra-articular injections of either HA (group 1) or @entity7676 (plasma rich in growth factors [PRGF] technique, group 2) for @entity75 of the talus. Thirty @entity75 , 15 per arm, received 3 consecutive intra-articular therapeutic injections and were followed for 28 weeks. The efficacy of the injections in reducing @entity158 and improving function was assessed at each visit using the American Orthopaedic Foot and Ankle Society (AOFAS) Ankle-Hindfoot Scale (AHFS); a visual analog scale (VAS) for @entity158 , stiffness, and function; and the subjective global function score. RESULTS: The majority of @entity1 were @entity1 (n = 23; 79%). The AHFS score improved from 66 and 68 to 78 and 92 in groups 1 and 2, respectively, from baseline to week 28 (P < .0001), favoring @entity7676 (P < .05). Mean VAS scores (1 = asymptomatic, 10 = severe symptoms) decreased for @entity158 (group 1: 5.6 to 3.1; group 2: 4.1 to 0.9), stiffness (group 1: 5.1 to 2.9; group 2: 5.0 to 0.8), and function (group 1: 5.8 to 3.5; group 2: 4.7 to 0.8) from baseline to week 28 (P < .0001), favoring @entity7676 (P < .05 for stiffness, P < .01 for function, P > .05 for @entity158 ). Subjective global function scores, reported on a scale from 0 to 100 (with 100 representing healthy, preinjury function) improved from 56 and 58 at baseline to 73 and 91 by week 28 for groups 1 and 2, respectively (P < .01 in favor of @entity7676 ). CONCLUSION: Osteochondral lesions of the ankle treated with intra-articular injections of @entity7676 and HA resulted in a decrease in @entity158 scores and an increase in function for at least 6 months, with minimal adverse events. Platelet-rich plasma treatment led to a significantly better outcome than HA.

Platelet-rich plasma or hyaluronate in the management of XXXX of the talus.

@entity75 :: ('MESH:D001927', 'Disease') :: ['OCLs', 'osteochondral lesions'] @entity1 :: ('9606', 'Species') :: ['patients', 'men'] @entity7676 :: ('722', 'Gene') :: ['PRP'] @entity158 :: ('MESH:D010146', 'Disease') :: ['pain']
@entity75 :: (MESH:D001927,Disease) :: ['osteochondral lesions']
